DnB Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

DnB Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$94K	Buy	+30,607	New	+$118K	﹤0.01%	1217
2025 Q4	–	Sell	-313,707	Closed	-$1.53M	–	770
2025 Q3	$1.53M	Buy	+313,707	New	+$1.65M	0.01%	614
2025 Q2	–	Sell	-18,917	Closed	-$100K	–	764
2025 Q1	$100K	Sell	18,917 -66,448	-78%	-$484K	﹤0.01%	721
2024 Q4	$577K	Buy	+85,365	New	+$574K	﹤0.01%	653
2024 Q3	–	Sell	-33,119	Closed	-$248K	–	726
2024 Q2	$248K	Buy	+33,119	New	+$289K	﹤0.01%	682
2022 Q4	–	Sell	-26,086	Closed	-$277K	–	651
2022 Q3	$277K	Buy	+26,086	New	+$264K	﹤0.01%	638

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DnB Asset Management's RXRX Position: Q1 2026 in Review

DnB Asset Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 30,607 shares worth $94K. The stake represents ﹤0.01% of the portfolio and ranks #1217 among its holdings. This is a return to the name: DnB Asset Management previously reported a position in RXRX as recently as Q3 2025.

DnB Asset Management first reported a position in RXRX in Q3 2022 and has held it in 6 quarters since. The position peaked at $1.53M in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

DnB Asset Management held 30,607 shares of Recursion Pharmaceuticals worth $94K as of Q1 2026.
Recursion Pharmaceuticals was a new DnB Asset Management position in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of DnB Asset Management's portfolio in Q1 2026, its #1217 holding.
DnB Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 6 quarters since.
DnB Asset Management's Recursion Pharmaceuticals position peaked at $1.53M in Q3 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.